The DOI matches its Crossref record; 132 of the 133 references it cites were found in a registry or an index.
Myeloid-derived-suppressor cells as regulators of the immune system
Open accessAbstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that expand during cancer, inflammation and infection, and that have a remarkable ability to suppress T-cell responses. These cells constitute a unique component of the immune system that regulates immune responses in healthy individuals and in the context of various diseases. In this Review, we discuss the origin, mechanisms of expansion and suppressive functions of MDSCs, as well as the potential to target these cells for therapeutic benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD11b+Gr1+ myeloid cells are a heterogeneous group with previously identified roles in tumor angiogenesis and T cell immunosuppression (Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009; Shojaei et al., 2007).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Gabrilovich and Nagaraj, 2009
In the citing paper
“MDSCs play a role in the immune system through their suppressive action on T cells (116).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [116]
In the citing paper
“Through different mediators such as arginase 1, Inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), and peroxynitrite, MDSCs attenuate the activity of Teffs and NK cells (Gabrilovich and Nagaraj, 2009), regulate the differentiation of Tregs (Huang et al., 2006), and induce an immunosuppressive phenotype in macrophages (Sinha et al., 2007).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Gabrilovich and Nagaraj, 2009
In the citing paper
“On a similar note, immunosuppressive myeloid cells can be differentiated/polarized for anti‐tumor phenotypes [88, 89].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“In addition, TAMs produce several cytokines (reviewed in Ref”
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 1×
“MDSCs express high levels of both arginase 1 and iNOS, and a direct role for both of these enzymes in the inhibition of T-cell function is well established; this has been reviewed recentl”
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 1×
“However,as these non-immunological aspects of MDSC biology have recently been reviewed elsewher”
Reactive oxygen species: role in the development of cancer and various chronic conditions.
Waris, G., & Ahsan, H. (2006) · Journal of Carcinogenesis · doi:10.1186/1477-3163-5-14 · Cited by 1,447
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435 · cited 1×
“, CD115 (also known as macrophage colony-stimulating factor receptor (M-CSF) and CSF1”
Movahedi, K., Guilliams, M., van den Bossche, J., den Bergh, R. V., Gysemans, C., Beschin, A., Baetselier, P. D., & Ginderachter, J. V. V. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,352
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Self-citationDiaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176
Self-citation
Flagged first, then by citations
1 of the 133 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Fricke, I. et al. Treatment of cancer patients with VEGF-Trap overcomes defects in DC differentiation but is insufficient to improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840–4848 (2007). · DOI
Cited by
Sorted by citations
Items 101–200 of 1,053
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 711
Cytokines in Cancer Immunotherapy
Lee, S. Y., & Margolin, K. A. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 718
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 706
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Origins of tumor-associated macrophages and neutrophils
Cortez‐Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B. S., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 702
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Zamarron, B. F., & Chen, W. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.651 · Cited by 681
Diverse novel functions of neutrophils in immunity, inflammation, and beyond
Mócsai, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122220 · Cited by 706
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M. S. C., & Yao, Y. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 677
Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 665
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Pozzo, F. D., Soldani, C., Zilio, S., Avella, D., Palma, A. D., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 685
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Bobrie, A., Krumeich, S., Reyal, F., Recchi, C., Moita, L. F., Seabra, M. C., Ostrowski, M., & Théry, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0925 · Cited by 670
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer
Eruslanov, E. B., Bhojnagarwala, P. S., Quatromoni, J. G., Stephen, T. L., Ranganathan, A., Deshpande, C. G., Akimova, T., Vachani, A., Litzky, L. A., Hancock, W. W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77053 · Cited by 653
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Kumar, V. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 665
M1/M2 macrophages and their overlaps – myth or reality?
Strizova, Z. O., Benešová, I., Bartolini, R., Novysedlák, R., Cecrdlova, E., Foley, L. K., & Stříž, I. (2023) · Clinical Science · doi:10.1042/cs20220531 · Cited by 709
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D. R., Seehawer, M., Zender, L., & Heikenwälder, M. F. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 639
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D. H., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 631
Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options
Liu, D., Huang, S., Sun, J., Zhang, H., Cai, Q., Gao, C., Li, L., Cao, J., Xu, F., Zhou, Y., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00422-y · Cited by 646
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy
Komohara, Y., Fujiwara, Y., Ohnishi, K., & Takeya, M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.009 · Cited by 615
Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.003 · Cited by 609
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 626
Multifaceted roles of PGE2 in inflammation and cancer
Nakanishi, M., & Rosenberg, D. W. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0342-8 · Cited by 611
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 610
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H. N., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Hossain, F. M., Al-Khami, A. A., Wyczechowska, D. D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 614
Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000901 · Cited by 582
Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity
Long, X., Wong, C. C., Tong, L., Chu, E. S. H., Ho Szeto, C., Go, M. Y. Y., Coker, O. O., Chan, A. W. H., Chan, F. K. L., Sung, J. J. Y., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0541-3 · Cited by 557
Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S. J., West, B. L., Bollag, G. E., McBride, W. H., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 589
Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernández, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200939903 · Cited by 568
Youn, J., & Gabrilovich, D. I. (2010) · European Journal of Immunology · doi:10.1002/eji.201040895 · Cited by 568
Self-citationRegulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P., & Verdeil, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.80 · Cited by 570
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu‐Lieskovan, S., Mok, S., Moreno, B. H., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comı́n-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 576
Tsilimigras, D. I., Brodt, P., Clavien, P., Muschel, R. J., D'Angelica, M. I., Endo, I., Parks, R. W., Doyle, M. B., de Santibáñes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 584
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Lü, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 546
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J. H., Balmain, A., Bar‐Sagi, D., Bernards, R., Bullman, S., DeGregori, J. V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 578
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
“MDSCs and Tregs have been shown to exert suppressive function on T cells, thereby possibly counteracting the beneficial effect of ipilimumab (28, 45).”
BackgroundLymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity
Swartz, M. A., & Lund, A. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3186 · Cited by 544
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 546
Alshetaiwi, H. S., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G. A., Evans, K. T., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 532
Dental Pulp Defence and Repair Mechanisms in Dental Caries
Farges, J., Alliot‐Licht, B., Renard, E., Ducret, M., Gaudin, A., Smith, A. J., & Cooper, P. R. (2015) · Mediators of Inflammation · doi:10.1155/2015/230251 · Cited by 535
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair
Willenborg, S., Lucas, T., van Loo, G., Knipper, J. A., Krieg, T., Haase, I., Brachvogel, B., Hammerschmidt, M., Nagy, A., Ferrara, N., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403386 · Cited by 534
Mira, J. C., Gentile, L. F., Mathias, B. J., Efron, P. A., Brakenridge, S. C., Mohr, A. M., Moore, F. A., & Moldawer, L. L. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002074 · Cited by 526
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Condamine, T., Ramachandran, I., Youn, J., & Gabrilovich, D. I. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-052304 · Cited by 533
Self-citationMyeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand‐Rosenberg, S. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 534
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R., & Kim‐Schulze, S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 529
Rao, L., Bu, L., Xu, J., Cai, B., Yu, G., Yu, X., He, Z., Huang, Q., Li, A., Guo, S., et al. (2015) · Small · doi:10.1002/smll.201502388 · Cited by 526
Reactive Oxygen Species in the Immune System
Yang, Y., Bazhin, A. V., Werner, J., & Karakhanova, S. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2012.755176 · Cited by 523
Youn, J., Collazo, M. M., Shalova, I. N., Biswas, S. K., & Gabrilovich, D. I. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311177 · Cited by 510
Self-citationSTAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J. L., Blosser, R. L., Tam, A. J., Bruno, T. C., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 522
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Obermajer, N., Muthuswamy, R., Lesnock, J. L., Edwards, R. P., & Kaliński, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 511
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 507
Katzenelenbogen, Y., Sheban, F., Yalin, A., Yofe, I., Svetlichnyy, D., Jaitin, D. A., Bornstein, C., Moshe, A., Keren-Shaul, H., Cohen, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.032 · Cited by 498
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Anders, H., & Ryu, M. (2011) · Kidney International · doi:10.1038/ki.2011.217 · Cited by 502
Disis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 504
VISTA Regulates the Development of Protective Antitumor Immunity
Mercier, I. L., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P. A., Noelle, R. J., & Wang, L. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 498
Fibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 505
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 496
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 492
Spiegel, A., Brooks, M. W., Houshyar, S., Reinhardt, F., Ardolino, M., Fessler, E., Chen, M. B., Krall, J. A., Cock, J. M. D., Zervantonakis, I. K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1157 · Cited by 492
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 473
Obermajer, N., Muthuswamy, R., Odunsi, K. O., Edwards, R. P., & Kaliński, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 480
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 502
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 475
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T. B., Cho, H.-I., Antonia, S. J., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 476
Self-citationHailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X.-F., Dorta-Estremera, S. M., Greeley, N. R., Nitti, G., Peng, W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3105 · Cited by 472
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Inflammation and oncogenesis: a vicious connection
Grivennikov, S. I., & Karin, M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.004 · Cited by 474
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 455
S100A8/A9: From basic science to clinical application
Pruenster, M., Vogl, T., Roth, J., & Sperandio, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.015 · Cited by 463
Neutrophils: Cinderella of innate immune system
Kumar, V., & Sharma, A. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.08.012 · Cited by 455
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 457
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
The immunology of renal cell carcinoma
Diaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 447
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., et al. (2013) · Neoplasia · doi:10.1593/neo.13706 · Cited by 494
The determinants of tumour immunogenicity
Blankenstein, T. J. F., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3246 · Cited by 454
Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 455
Hough, K. P., Curtiss, M. L., Blain, T. J., Liu, R.-M., Trevor, J., Deshane, J. S., & Thannickal, V. J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00191 · Cited by 432
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzyńska, Z., Jasiński, M., Nowis, D., & Gołąb, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 446
Cui, T. X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R. D., Roh, M. H., Vatan, L., Szeliga, W., Mao, Y., Thomas, D. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.025 · Cited by 434
Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.044 · Cited by 418
“…in clo (I) Representative IF confocal images showing the percentage of pHP1g-positiv mean ± SEM. retains increased levels of immunostimulatory chemokine such as MCP-1, previously shown to activate senescence surveillance (Gabrilovich and Nagaraj, 2009; Xue et al., 2007; Zitvogel et al., 2008).”
Neutrophils in Cancer: Two Sides of the Same Coin
Uribe‐Querol, E., & Rosales, C. (2015) · Journal of Immunology Research · doi:10.1155/2015/983698 · Cited by 436
Update on Neutrophil Function in Severe Inflammation
Mortaz, E., Alipoor, S. D., Adcock, I. M., Mumby, S. E., & Koenderman, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02171 · Cited by 433
The pre-metastatic niche: finding common ground
Sceneay, J., Smyth, M. J., & Möller, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9420-1 · Cited by 422
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402
“…exert T cell inhibition mainly through ROS production, whereas Mo-MDSCs suppress T cells predominantly via the enzymes Arg1 and inducible nitric oxide synthase (iNOS) and through the production of reactive nitrogen species (Gabrilovich and Nagaraj, 2009; Movahedi et al., 2008; Youn et al., 2008).”
InfluentialBone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P. D., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2020) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 442
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi‐Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 430
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Metadata
- Authors
- Gabrilovich, D. I., & Nagaraj, S.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- Venue
- Nature Reviews Immunology
- Published
- 2009-03
- Volume
- 9
- Issue
- 3
- Pages
- 162-174
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC2828349
- OpenAlex
- W2004150448
- Cited by
- 6,753
- References
- 133
- Citations by year
- 2026: 267 · 2025: 335 · 2024: 384 · 2023: 418 · 2022: 488 · 2021: 537 · 2020: 498 · 2019: 384 · 2018: 433 · 2017: 409 · 2016: 405 · 2015: 422 · 2014: 403 · 2013: 430 · 2012: 378
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Repositorio Institucional E-DocUR (Universidad Del Rosario) (submittedVersion)
- Funders
- National Cancer Institute (R01CA084488, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- myeloid-derived suppressor cells, T cell suppression, tumor immunosuppression, inflammation, infection, immune regulation
- MeSH terms
- Animals, Cell Movement, Communicable Diseases, Humans, Immune System, Immune Tolerance, Inflammation, Lymphocyte Activation, Neoplasms, Stem Cells, T-Lymphocytes, Myeloid Cells, Myelopoiesis, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
